Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aclaris Therapeutics (ACRS) shares

Learn how to easily invest in Aclaris Therapeutics shares.

Aclaris Therapeutics is a biotechnology business based in the US. Aclaris Therapeutics stocks (ACRS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $17.79 – an increase of 3.7% over the previous week. Aclaris Therapeutics employs 57 staff and has a trailing 12-month revenue of around $6.8 million.

How to buy shares in Aclaris Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ACRS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Aclaris Therapeutics stock price (NASDAQ:ACRS)

Use our graph to track the performance of ACRS stocks over time.

Aclaris Therapeutics shares at a glance

Information last updated 2022-01-23.
Latest market close$10.10
52-week range$9.26 - $30.38
50-day moving average $13.28
200-day moving average $17.25
Wall St. target price$34.80
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.55

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Aclaris Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Aclaris Therapeutics price performance over time

Historical closes compared with the close of $10.1 from 2022-01-27

1 week (2022-01-19) -0.39%
1 month (2021-12-25) N/A
3 months (2021-10-25) N/A
6 months (2021-07-29) -42.58%
1 year (2021-01-29) -51.33%
2 years (2020-01-29) 642.65%
3 years (2019-01-29) 50.30%
5 years (2017-01-27) 26.93

Aclaris Therapeutics financials

Revenue TTM $6.8 million
Gross profit TTM $-27,989,000
Return on assets TTM -21.71%
Return on equity TTM -63.46%
Profit margin 0%
Book value $3.54
Market capitalisation $596.4 million

TTM: trailing 12 months

Aclaris Therapeutics share dividends

We're not expecting Aclaris Therapeutics to pay a dividend over the next 12 months.

Aclaris Therapeutics share price volatility

Over the last 12 months, Aclaris Therapeutics's shares have ranged in value from as little as $9.26 up to $30.375. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aclaris Therapeutics's is 0.4921. This would suggest that Aclaris Therapeutics's shares are less volatile than average (for this exchange).

Aclaris Therapeutics overview

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. .

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site